US EditionPublished • loading... • Updated
Myosin Therapeutics Invited to Present at Two South Florida Life Sciences Conferences
Myosin Therapeutics showcases MT-125, a novel glioblastoma treatment in Phase 1/2 trials, at two South Florida events attracting investors and life sciences partners.
- Myosin Therapeutics said it was invited to present at the Investival Showcase on March 10 and BioFlorida's South Florida Life Sciences Showcase later in March.
- Myosin Therapeutics' recent progress advancing its clinical-stage oncology pipeline and engagement with partners prompted invitations to two South Florida life sciences events.
- Courtney Miller, PhD, Chief Executive Officer of Myosin Therapeutics, will present the nanomotor-dependency platform and MT-125, a first-in-class inhibitor targeting non-muscle myosin IIA and IIB to induce tumor cell death.
- Planned meetings include investors and pharmaceutical companies, with Myosin participating in partnering discussions at the Investival Showcase and BioFlorida sessions, following recent investor meetings.
- With Orphan Drug and Fast Track designations, the MT-125 program is in Phase 1/2 for glioblastoma at Mayo Clinic and expanded into several other aggressive cancers.
Insights by Ground AI
32 Articles
32 Articles
The Courier-Tribune+31 Reposted by 31 other sources
Myosin Therapeutics Invited to Present at Two South Florida Life Sciences Conferences
JUPITER, Fla., March 9, 2026 /PRNewswire/ -- Myosin Therapeutics today announced it has been invited to present at two upcoming South Florida life sciences events highlighting emerging biotechnology innovation and regional industry growth. On March 10, the company will participate…
Coverage Details
Total News Sources32
Leaning Left3Leaning Right4Center9Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 19%
C 56%
R 25%
Factuality
To view factuality data please Upgrade to Premium
